You are here

  • Home
  • Archive
  • Volume 75, Issue 7
  • Response to: ‘Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update’ by Goswami et al

Article Text

Article menu

Download PDFPDF

Electronic pages
Correspondence response
Response to: ‘Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update’ by Goswami et al
Free
  1. Tanja Stamm1,2,
  2. Michaela Stoffer1,2,
  3. Josef Smolen2,3
  1. 1Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria
  2. 2Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
  3. 3Department of Internal Medicine, Centre for Rheumatic Diseases, Hietzing Hospital, Vienna, Austria
  1. Correspondence to Professor Josef Smolen, Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, 1090 Vienna, Austria; josef.smolen{at}wienkav.at

https://doi.org/10.1136/annrheumdis-2016-209499

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank the authors of the letter1 for their comments on our systematic literature review (SLR)2 that aimed to compare a target-oriented approach with routine management in the treatment of rheumatoid arthritis to allow an update of the treat-to-target (T2T) recommendations.3 In addition to clinical, functional and structural changes as endpoints, comorbidities, cardiovascular risk, work productivity and education as well as patient self-assessment were investigated as outcomes in our SLR. Furthermore, our SLR aimed to update the literature review conducted by Schoels et al,4 which was performed in 2009. Therefore, we included studies published from 2009 to 2014.

    We did not explicitly look into cost-effectiveness of biologic disease modifying antirheumatic drugs. The …

    View Full Text

    Linked Articles